ClinicalTrials.gg
CompletedNCT00444613Updated Jun 18, 2023

A Study in Patients With Amyotrophic Lateral Sclerosis (ALS)

A Phase 2/3 interventional study of E0302 (mecobalamin) and E0302 (mecobalamin) in Amyotrophic Lateral Sclerosis (ALS), sponsored by Eisai Co., Ltd.. Completed at 44 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2023-06-18.

Sponsored by Eisai Co., Ltd. · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
373
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan — 2 open to participants now, 4 under way, 2 of them phase 3. Amyotrophic Lateral Sclerosis · Japan.

Enrollment
2nd of 20
373 · median 136
Started
2007
with 1 other
Phase 2/3
2 of 21
none open now
Registered
2nd of 21
by date
Lead sponsor
3 of 21
Eisai Co., Ltd.

Among the 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan, this one is the 2nd largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2007, is one of 2 in phase 2/3, and was the 2nd registered.

Amyotrophic Lateral Sclerosis

980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

2 of the 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the efficacy and confirm the safety of E0302 in patients with Amyotrophic Lateral Sclerosis (ALS) by assessing changes in scores of survival rate and functional rating scale.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis (ALS)

Keywords

  • Amyotrophic Lateral Sclerosis (ALS)
  • motor neurons
  • muscular atrophy
  • Lou Gehrig's Disease
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who are able to submit written . If patients are duly capable of study consent but are unable to sign (or affix a seal) by themselves due to aggravation of disease condition, written informed consent can be obtained from a legally authorized representative who can sign on behalf of the patients after confirming the patients' agreement to study participation.
  2. Patients who are aged 20 years or older at the time of obtaining informed consent.
  3. Patients who have clinically definite ALS, clinically probable ALS, or clinically probable-laboratory supported ALS as specified in the revised El Escorial Airlie House diagnostic criteria.
  4. Patients who are at stage 1 or 2 of the severity criteria for ALS.
  5. Patients within 3-year elapsed time period from disease onset at the start of observation period.
  6. Patients who can visit study site for out-patient treatment.

Exclusion criteria

Exclusion Criteria:

  1. Patients who underwent tracheostomy.
  2. Patients who experienced non-invasive positive pressure ventilation.
  3. Patients whose percent-predicted forced vital capacity (%FVC) is >=60%.
  4. Patients with multiple disturbances of conduction detected by nerve conduction test.
  5. Patients with neurological symptom(s) due to vitamin B12 deficiency.
  6. Patients who initiated newly introduced riluzole therapy after starting the observation period. Or those who received dose escalation or resumed administration of riluzole therapy after previous down titration or discontinuation.
  7. Patients with cognitive impairment.
  8. Pregnant women or women with a possibility of becoming pregnant.
  9. Patients or their partners who are not willing to use reliable .
  10. Patients with severe disease in the renal, cardiovascular, hematological, or hepatic system (severe disease will be judged referring to "Ministry of Health, Labor and Welfare" (MHLW) Drug Safety Dept. Notification No. 80, Drug Safety Classification Criteria for Severity of Adverse Drug Reaction by Medicinal Products, Grade 3).
  11. Patients with malignant tumor.
  12. Patients who participated in another clinical study within 12 weeks before starting the observation period.
  13. Patients with present illness or history of drug allergy or severe allergic disease (anaphylactic shock).
  14. Patients who are judged to be ineligible for study entry by the investigator or subinvestigator.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
373 participants (actual)

Study arms

  • Experimental
    E0302 25 mg

    Drug: E0302 (mecobalamin)

  • Experimental
    E0302 50 mg

    Drug: E0302 (mecobalamin)

  • Placebo comparator
    3

    Drug: Placebo

Interventions

  • Intramuscular injection, mecobalamin 25 mg twice a week for 3.5 years.

    Also known as: mecobalamin

  • Intramuscular injection, mecobalamin 50 mg twice a week for 3.5 years.

    Also known as: mecobalamin

  • DrugPlacebo

    Intramuscular injection, placebo twice a week for 3.5 years.

06

What researchers measure

Primary outcomes

  1. Survival rate

    Time frame: Every 3 months.

  2. Functional rating scale.

    Time frame: Every 3 months.

Secondary outcomes

  1. Manual Muscle Test (MMT)

    Time frame: Every 3 months.

  2. Percent-predicted forced vital capacity (%FVC)

    Time frame: Every 3 months.

07

Study locations

44 sites
  • Nagoya-shi, Aichi, Japan
  • Akita-shi, Akita, Japan
  • Aomori-shi, Aomori, Japan
  • Chiba-shi, Chiba, Japan
  • Touon-shi, Ehime, Japan
  • Fukuoka-shi, Fukuoka, Japan
  • Kitakyusyu-shi, Fukuoka, Japan
  • Fukushima-shi, Fukushima, Japan
  • Maebashi-shi, Gunma, Japan
  • Higashihiroshima-shi, Hiroshima, Japan
  • Miyoshi-shi, Hiroshima, Japan
  • Otake-shi, Hiroshima, Japan
  • Sapporo-shi, Hokkaido, Japan
  • Kanazawa-shi, Ishikawa, Japan
  • Ichinoseki-shi, Iwate, Japan
  • Sagamihara-shi, Kanagawa, Japan
  • Yokohama-shi, Kanagawa, Japan
  • Nangoku-shi, Kochi, Japan
  • Kyoto-shi, Kyoto, Japan
  • Tsu-shi, Mie, Japan
  • Sendai-shi, Miyagi, Japan
  • Watari-gun, Miyagi, Japan
  • Nagano-shi, Nagano, Japan
  • Higashisonogi-gun, Nagasaki, Japan
  • Kashiwazaki-shi, Niigata, Japan
  • Niigata-shi, Niigata, Japan
  • Tsukubo-gun, Okayama, Japan
  • Ginowan-shi, Okinawa, Japan
  • Toyonaka-shi, Osaka, Japan
  • Hasuda-shi, Saitama, Japan
  • Saitama-shi, Saitama, Japan
  • Otsu-shi, Shiga, Japan
  • Hamamatsu-shi, Shizuoka, Japan
  • Shizuoka-shi, Shizuoka, Japan
  • Shimotsuke-shi, Tochigi, Japan
  • Tokushima-shi, Tokushima, Japan
  • Yoshinogawa-shi, Tokushima, Japan
  • Bunkyo-ku, Tokyo, Japan
  • Kodaira-shi, Tokyo, Japan
  • Ota-ku, Tokyo, Japan
  • Wakayama-shi, Wakayama, Japan
  • Yonezawa-shi, Yamagata, Japan
  • Shimonoseki-shi, Yamaguchi, Japan
  • Yanai-shi, Yamaguchi, Japan
08

References and documents

Publications

  • Kaji R, Imai T, Iwasaki Y, Okamoto K, Nakagawa M, Ohashi Y, Takase T, Hanada T, Shimizu H, Tashiro K, Kuzuhara S. Ultra-high-dose methylcobalamin in amyotrophic lateral sclerosis: a long-term phase II/III randomised controlled study. J Neurol Neurosurg Psychiatry. 2019 Apr;90(4):451-457. doi: 10.1136/jnnp-2018-319294. Epub 2019 Jan 13. PubMed 30636701 ↗
  • Ikeda K, Iwasaki Y, Kaji R. Neuroprotective effect of ultra-high dose methylcobalamin in wobbler mouse model of amyotrophic lateral sclerosis. J Neurol Sci. 2015 Jul 15;354(1-2):70-4. doi: 10.1016/j.jns.2015.04.052. Epub 2015 May 8. PubMed 25982504 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2007, a primary completion of Mar 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2007
First posted
Mar 8, 2007
Start
Apr 2007
Primary completionActual
Mar 2014
CompletionActual
Jul 2014
Last update
Jun 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00444613
Lead sponsor
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Mar 8, 2007
Start date
Apr 2007
Primary completion
Mar 2014
Completion
Jul 2014
Last update
Jun 18, 2023

Study contacts

Kazunori Saeki
study director · Neuroscience Clinical Development Section. JAC PCU. Eisai Co., Ltd.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mecobalamin

Start the discussion